| Publisher’s Note: Join Fierce Biotech Editors and industry leaders at the Fierce Biotech Summit to network and gain exclusive insights. Don’t miss out — register now! |
Today’s Big NewsSep 12, 2024 |
|
Still Time to Shine! Submission deadline for the Fierce Life Sciences Innovation Awards have been extended to September 12. Click to submit your entry and learn more about what winner's will receive.
|
|
| By Nick Paul Taylor Moderna has vowed to cut annual R&D spending by $1.1 billion by 2027. The decision to shrink the budget by more than 20% follows commercial setbacks that have persuaded the biotech to take a “more selective and paced approach” to drug development. |
|
|
|
By Nick Paul Taylor Sanofi has made a late entry to the radioligand party, paying 100 million euros ($110 million) upfront for global rights to a neuroendocrine tumor treatment that is nearing a filing for approval. |
By James Waldron Just four months after Sanofi bet $80 million upfront on Fulcrum Therapeutics’ losmapimod, the program has ended in a phase 3 failure. |
By James Waldron After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has delivered the goods in the all-important population of older adults. |
|
Partner with us for vaccine manufacturing that expertly integrates novel analytical and process-related technologies with your program's unique needs, ensuring efficient tech transfer and rapid scaling. Grow with us.
|
|
By Gabrielle Masson Cancer biotech Oncternal Therapeutics is folding all its clinical trials and laying off staff, turning its energy toward exploring strategic alternatives such as asset sales, a merger or acquisition. |
By Fraiser Kansteiner Lilly revealed that its weekly insulin candidate efsitora alfa met its primary endpoints for reducing the A1C measure of blood sugar across two more trials in the company's five-study phase 3 development program. |
By James Waldron After F2G’s first attempt to get a brand-new class of antifungal to market was derailed by the FDA, the U.K.-based biotech has secured $100 million in fresh funding to bankroll another push towards commercialization. |
By Gabrielle Masson Vironexis Biotherapeutics has unveiled with $26 million and a clinical-trial-ready gene therapy that has already nabbed FDA fast track and rare pediatric disease tags. |
By Darren Incorvaia Hundreds of millions of people who live in, or are descended from, regions where the malaria-causing protozoan Plasmodium vivax is prevalent have inherited a unique blood type that evolved to prevent malaria infection. People with the Duffy null phenotype—who are primarily of African and Middle Eastern descent—have red blood cells that lack a surface protein called the Duffy antigen, which is what P. vivax uses to infect cells. |
By Nick Paul Taylor The FDA has faulted AbbVie’s promotion of the migraine drug Ubrelvy, calling the company out for an ad featuring Serena Williams that went out of bounds with claims about how quickly the product relieves symptoms. |
By Noah Tong House members voted in support of association health plans, the latest development in a yearslong battle that some say is an attempt to weaken the Affordable Care Act. |
Fierce podcastsDon’t miss an episode |
| | In this week's episode of "The Top Line," we’re looking at what goes into manufacturing and supply of flu vaccines. |
|
|---|
|
|
| Whitepaper Facing roadblocks in drug development? Uncover how phase-appropriate technology transfers can help you navigate challenges and speed up your journey to market. Sponsored by: Veranova |
| WhitepaperWe interviewed dozens of biopharma leaders on the critical success factors for building a Best Practice commercial organization. This report shares what we learned. Sponsored by: Blue Matter Consulting |
| WhitepaperFinding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
